While BRAF mutations were found to correlate only with the presence of focal tall cell futures and the development of tumor recurrences, RAS mutations, as formerly shown [40], demonstrated to be significantly associated to age, DMs at diagnosis and/or during the follow-up, metachronous DMs, developed during the follow-up, and DOD patient status. The gene discussed is BRAF; the disease is neoplasm.